Sign in

CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company

X4 Pharmaceuticals, Inc

Sign in to watch
Ticker
XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273181608
Phone
857-529-8300
Business address
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
Former names
Arsanis, Inc.
  1. 4 Grant or award Chief Scientific Officer acquired 230,645 shares (grant or award)
  2. 4 Grant or award President and CEO acquired 532,081 shares (grant or award)
  3. 4 Grant or award Chief Operating Officer acquired 230,645 shares (grant or award)
  4. 4 Grant or award Director acquired 90,000 shares (grant or award)
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market sale Chief Operating Officer sold 2,642 shares at $1.25 ($3,300)
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market buy Director bought 25,000 shares at $1.20 ($29,875)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market sale Interim Chief Medical Officer sold 130,056 shares at $1.06 ($137,859)
  11. 4 Open-market sale Chief Operating Officer sold 464 shares at $1.89 ($877)
  12. 4 Open-market sale Chief Financial Officer sold 2,641 shares at $1.89 ($4,991)
  13. 4 Open-market sale Chief Operating Officer sold 857 shares at $1.93 ($1,654)
  14. 4 Open-market sale Chief Financial Officer sold 5,417 shares at $1.93 ($10,455)
  15. 4 Open-market sale President and CEO sold 6,724 shares at $1.92 ($12,910)
  16. 4 Open-market sale Chief Operating Officer sold 857 shares at $2.23 ($1,911)
  17. 4 Open-market sale Chief Financial Officer sold 5,417 shares at $2.22 ($12,026)
  18. 4 Open-market sale President and CEO sold 6,724 shares at $2.23 ($14,995)
  19. 4 Grant or award Director acquired 45,000 shares (grant or award)
  20. 4 Grant or award Director acquired 45,000 shares (grant or award)

Page 5 of 17 · 329 filings